Congress 116 - HR 2339 - Protecting American Lungs and Reversing the Youth Tobacco Epidemic Act of 2020

Sponsor

Cosponsors

Topics

Administrative law and regulatory procedures Cancer Cardiovascular and respiratory health Child health Civil actions and liability Congressional oversight Consumer affairs Department of Health and Human Services Digestive and metabolic diseases Drug safety, medical device, and laboratory regulation Drug, alcohol, tobacco use Food and Drug Administration (FDA) Government information and archives Government studies and investigations Health Health care costs and insurance Health care coverage and access Health facilities and institutions Health information and medical records Health programs administration and funding Health promotion and preventive care Health technology, devices, supplies Marketing and advertising Medical research Medical tests and diagnostic methods Medicare Mental health Minority health Racial and ethnic relations Research administration and funding Retail and wholesale trades Sales and excise taxes State and local courts State and local government operations User charges and fees

Full Text

View Full Bill Text

Votes

Summary

Protecting American Lungs and Reversing the Youth Tobacco Epidemic Act of 2020

This bill revises requirements related to the safety, sale, and advertisement of tobacco products, including electronic nicotine delivery systems (e.g., e-cigarettes, e-hookah, e-cigars, and vape pens).

Among other requirements, the bill

requires the Food and Drug Administration (FDA) to implement regulations to require color graphics on the labeling of cigarette packages, depicting the negative health consequences of smoking;
requires the FDA to apply regulations on tobacco products to all tobacco products, including e-cigarettes;
generally prohibits the retail online sale of tobacco products, including electronic nicotine delivery systems;
prohibits flavors other than tobacco in a tobacco product;
prohibits the use of flavored products in an electronic nicotine delivery system, except in specified circumstances;
increases the user fees that the FDA collects from manufacturers and importers;
directs the FDA to regulate products containing nicotine not made or derived from tobacco plants (including nicotine from chemical synthesis, recombinant genetic technology, or extraction from non-tobacco plants);
imposes an excise tax on nicotine that has been extracted, concentrated, or synthesized;
provides funding through FY2025 to support public education regarding tobacco regulation, public awareness regarding the harms associated with tobacco use, outreach to medically underserved communities regarding tobacco-use prevention and cessation, research grants related to tobacco-use prevention and cessation, and grants to health centers for tobacco-use cessation treatment;
establishes and provides funding through FY2025 for a demonstration grant program to develop strategies for smoking cessation (including of the use of menthol-flavored tobacco products) in medically underserved communities;
beginning in 2024, waives coinsurance under Medicare for colorectal-cancer screening tests;
specifies that a health insurance plan may still be treated, for certain tax-deduction purposes, as a high-deductible plan even if it does not have a deductible for certain inhalers or nebulizers;
exempts certain cigars from premarket review requirements;
increases civil penalties for certain violations of restrictions on the sale of tobacco products; and
requires the Government Accountability Office to study e-cigarettes.

Actions

Mar 2, 2020

Received in the Senate and Read twice and referred to the Committee on Finance.
Feb 28, 2020

Motion to reconsider laid on the table Agreed to without objection.
Feb 28, 2020

On passage Passed by the Yeas and Nays: 213 - 195 (Roll no. 78). (text: CR H1257-1262)
Feb 28, 2020

Passed/agreed to in House: On passage Passed by the Yeas and Nays: 213 - 195 (Roll no. 78).
Feb 28, 2020

On motion to recommit with instructions Failed by the Yeas and Nays: 187 - 220 (Roll no. 77).
Feb 28, 2020

The previous question on the motion to recommit with instructions was ordered without objection.
Feb 28, 2020

Floor summary: DEBATE - The House proceeded with 10 minutes of debate on the Walden motion to recommit with instructions. The instructions contained in the motion seek to require the bill to be reported back to the House with an amendment to insert a new title at the end of the bill, "Born-Alive Abortion Survivors Protection."
Feb 28, 2020

Mr. Walden moved to recommit with instructions to the Committee on Energy and Commerce. (text: CR H1286-1287)
Feb 28, 2020

Considered as unfinished business. (consideration: CR H1286-1289)
Feb 28, 2020

POSTPONED PROCEEDINGS - Pursuant to clause 1(c) of Rule XIX, further proceedings on H.R. 2339 were postponed.
Feb 28, 2020

The previous question was ordered pursuant to the rule.
Feb 28, 2020

DEBATE - The House proceeded with 90 minutes of debate on H.R. 2339.
Feb 28, 2020

Rule provides for consideration of H.R. 2339 with 1 hour and 30 minutes of general debate. Motion to recommit with or without instructions allowed.
Feb 28, 2020

Considered under the provisions of rule H. Res. 866. (consideration: CR H1257-1286)
Feb 27, 2020

Rule H. Res. 866 passed House.
Feb 26, 2020

Rules Committee Resolution H. Res. 866 Reported to House. Rule provides for consideration of H.R. 2339 with 1 hour and 30 minutes of general debate. Motion to recommit with or without instructions allowed.
Feb 21, 2020

Placed on the Union Calendar, Calendar No. 324.
Feb 21, 2020

Reported (Amended) by the Committee on Energy and Commerce. H. Rept. 116-402.
Nov 19, 2019

Ordered to be Reported (Amended) by the Yeas and Nays: 28 - 24.
Nov 19, 2019

Committee Consideration and Mark-up Session Held.
Nov 13, 2019

Forwarded by Subcommittee to Full Committee (Amended) by Voice Vote .
Nov 13, 2019

Subcommittee Consideration and Mark-up Session Held.
Oct 16, 2019

Subcommittee Hearings Held.
Apr 19, 2019

Referred to the Subcommittee on Health.
Apr 18, 2019

Referred to the House Committee on Energy and Commerce.
Apr 18, 2019

Introduced in House

Amendments

Related Bills